~~<i id='96E13C03BD'><strike id='96E13C03BD'><tt id='96E13C03BD'><pre id='96E13C03BD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

knowledge

author：comprehensive 2025-09-27 23:32:09 - browse：27

People taking notes while sitting around a meeting table — Adobe

It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Better Therapeutics data on benefit with GLP

focus

entertainment

hotspot

knowledge

focus

PeterMarks,DirectoroftheCenterforBiologicsEvaluationandResearchattheFoodandDrugAdministration.SusanW

WSS

Weight loss drug costs may need more research, senator suggests

Akero's treatment for NASH falls short in cirrhosis study

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Astellas still sees hope in its gene therapy after four deaths

STAT Readout: Today's biotech news includes Sana and Amylyx

Morphosys mixed study results for blood cancer drug

explore

knowledge

focus

How one medical school became remarkably diverse

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

European regulators consider appeal over Amylyx ALS drug

Jerome Adams on the need for new antivirals for Covid

CRISPR pioneers react to Casgevy, first gene

Medicare details structure of new drug price negotiation program

Cancer cells are shown to suck energy source from immune cells

After affirmative action ruling, medical educators look to 'holistic review'

What's changing in Medicare's open enrollment this year?

entertainment

There’s no way to know how good AI health technologies are

Surge of respiratory disease in China has likely explanation

A fraught question for the kids of Alzheimer’s: Is it coming for us?

European regulators consider appeal over Amylyx ALS drug

Surge of respiratory disease in China has likely explanation

Researchers CRISPR chickens in bid to protect them from bird flu

hotspot

knowledge

knowledge

focus